Fat Modulates the Relationship between Sarcopenia and Physical Function in Nonobese Older Adults

It is intuitive to think that sarcopenia should be associated with declines in physical function though recent evidence questions this assertion. This study investigated the relationship between absolute and relative sarcopenia, with physical performance in 202 nonobese (mean BMI = 26.6 kg/ht2) community-dwelling older (mean age = 73.8 ± 5.9 years) adults. While absolute sarcopenia (appendicular skeletal mass (ASM)/ht2) was either not associated, or weakly associated with physical performance, relative sarcopenia (ASM/kg) demonstrated moderate (r = 0.31 to r = 0.51, P < 0.01) relationships with performance outcomes in both males and females. Knee extension strength (r = 0.27) and leg extension power (r = 0.41) were both related to absolute sarcopenia (P < 0.001) in females and not in males. Strength and power were associated with relative sarcopenia in both sexes (from r = 0.47 to r = 0.67, P < 0.001). The ratio of lean mass to total body mass, that is, relative sarcopenia, is an important consideration relative to physical function in older adults even in the absence of obesity. Stratifying these individuals into equal tertiles of total body fat revealed a trend of diminished regression coefficients across each incrementally higher fat grouping for performance measures, providing further evidence that total body fat modulates the relationship between sarcopenia and physical function

Nine years of comparative effectiveness research education and training: initiative supported by the PhRMA Foundation

The term comparative effectiveness research (CER) took center stage with passage of the American Recovery and Reinvestment Act (2009). The companion US$1.1 billion in funding prompted the launch of initiatives to train the scientific workforce capable of conducting and using CER. Passage of the Patient Protection and Affordable Care Act (2010) focused these initiatives on patients, coining the term ‘patient-centered outcomes research’ (PCOR). Educational and training initiatives were soon launched. This report describes the initiative of the Pharmaceutical Research and Manufacturers Association of America (PhRMA) Foundation. Through provision of grant funding to six academic Centers of Excellence, to spearheading and sponsoring three national conferences, the PhRMA Foundation has made significant contributions to creation of the scientific workforce that conducts and uses CER/PCOR

Program in Personalized Health Care

Abstract: Background: The increasing number of available cancer therapies render medical decision-making (MDM) less straightforward. Patients want to know about the outcomes of similarly treated patients. Objective: The goal of this study was to design a breast cancer dashboard (BCD) tool that presents survival information to support MDM activities. Methods: Clinical variables during the clinic visit were determined via provider meetings and evaluated for accessibility from medical databases. Women with breast cancer (BC) were interviewed about their health care experiences after cancer diagnosis. We created a cohort of BC adult women treated at our institution from 1995 to 2012, from which clinical scenarios were defined and used to test survival outcomes. For the BCD, a simple, graphical user interface was built to present point-of-care clinical and survival data. Results: It is feasible to build the BCD using our institution&apos;s databases and generate survival plots to facilitate MDM activities. Patients with early-stage BC had the highest survival rate (82.3%) and the longest mean life years of 7.0 (SD 4.5) years. In late-stage BC, poor prognosis outweighs the influence of number of comorbidities on mortality. The BCD tool promotes more predictive, personalized, and collaborative health care. ABOUT THE AUTHORS The authors work across the University of Utah Health Sciences in oncology clinical practice, bioinformatics, and pharmacotherapy outcomes research. Our work is aimed at improving patient care via outcomes research and assessment. The Center&apos;s personnel have expertise in health economics, modeling, various clinical subspecialties (including oncology), drug information, statistical analysis and programming, and database management. PUBLIC INTEREST STATEMENT As more breast cancer treatment options become available, the shared medical decision-making relationship between physician and patient is becoming less straightforward. To support this important interaction, we have created an institution-specific medical communication tool. Decision aids have been shown to improve the health care experience of patients and ultimately lead to the achievement of higher-quality decisions. Our communication tool, named the breast cancer dashboard (BCD), was designed to be used during the clinic visit. It specifically address patients&apos; needs to know about the survival outcomes of similar patients treated at our cancer specialty hospital. The BCD brings together comprehensive and breast cancerspecific clinical information. It allows both the provider and patient to navigate the information using a patient-friendly graphic interface. By enhancing shared decision-making, there would be a shift toward patient care that is more predictive, preventive, personalized, and collaborative

Trends in Pharmaceutical Expenditures: The Impact on Drug Benefit Design

Annual national spending for pharmaceutical agents was increasing at a rapid pace during the late 1990s and early part of the 21st century, outpacing increases in spending on hospital care and on physician services, which had dominated the industry in the 1970s. In the past few years, however, this trend has shifted, resulting in a lower growth rate in 2005. The reasons for these trends of increases and subsequent declines are explained in this article, including the slower pace of increase in generics and the increasing role of biologic agents in the rate of pharmaceutical price inflation. The sharp increases in drug spending led to changes in prescription drug benefit designs that have not been fully tested. The recent decline creates an opportunity for health plans to evaluate the value of current and new strategies and implement value-based benefit designs in accordance with the shifting focus in healthcare toward value-based patient care. [AHDB, 2008;1(4):29-34.

Antiplatelet Medication Management in Patients Hospitalized With Ischemic Stroke

Purpose. The use of antiplatelet agents in patients hospitalized with ischemic stroke was studied. Methods. Patients with a primary or secondary diagnosis of noncardiogenic, thrombotic ischemic stroke from January 2002 through December 2004 were included in the analysis. Patients were then subdivided into four treatment groups and one no-treatment group based on whether they were charged for any of four antiplatelet regimens (low-dose aspirin [≤325 mg daily], extended-release dipyridamole 200 mg with aspirin 25 mg, clopidogrel 75 mg, and clopidogrel 75 mg [as the bisulfate] plus low-dose aspirin) at any time during hospitalization. Patients who did not receive any of these medications during hospitalization were defined as the no-treatment group. A patient\u27s illness severity was measured and compared with other patients in the data set. Results. A total of 44,108 patients were assigned to the treatment group, and 14,255 patients were assigned to the no-treatment group. In general, longer lengths of stay and higher institutional costs were associated with the no-treatment group. Patients in the no-treatment group consistently displayed more comorbid conditions than did patients in the treatment group. The no-treatment group exhibited higher usage rates of both fibrinolytic agents and vitamin K. More patients in the treatment group were discharged to home or rehabilitation, while more patients in the no-treatment group were either discharged to another nursing facility or died before discharge. Conclusion. A retrospective analysis of a large national hospital database revealed that one quarter of patients who suffered an acute stroke did not receive antiplatelet drugs during their patient stay. Outcomes for such patients were poorer than for patients who had received antiplatelet therapy